Enzymotec Ltd
ENZY
ENZY was delisted on the 10th of January, 2018.
34 hedge funds and large institutions have $57.2M invested in Enzymotec Ltd in 2016 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 13 increasing their positions, 13 reducing their positions, and 2 closing their positions.
0% more funds holding
Funds holding: 34 → 34 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
0% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 13
15% less capital invested
Capital invested by funds: $67.3M → $57.2M (-$10.1M)
Top Buyers
| 1 |
TM
Tiger Management
New York
|
+$803K |
| 2 |
Millennium Management
New York
|
+$572K |
| 3 |
JHIU
Janus Henderson Investors US
Denver,
Colorado
|
+$334K |
| 4 |
State Street
Boston,
Massachusetts
|
+$153K |
| 5 |
Renaissance Technologies
New York
|
+$139K |
Top Sellers
| 1 |
Goldman Sachs
New York
|
-$1.74M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$282K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$160K |
| 4 |
PC
Paulson & Co
New York
|
-$146K |
| 5 |
CAM
ClariVest Asset Management
San Diego,
California
|
-$90K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
JP Morgan Chase
New York
| $37K | +$13.6K | +1,700 | +48% |
|
27
Morgan Stanley
New York
| $35K | -$57.7K | -7,197 | -59% |
|
|
CLOS
28
Compagnie Lombard Odier SCmA
1204 Geneva,
Switzerland
| $28K | – | – | – |
|
|
PCM
29
Penserra Capital Management
Orinda,
California
| $24K | +$7.01K | +875 | +33% |
|
30
UBS Group
Zurich,
Switzerland
| $18K | +$12K | +1,497 | +154% |
|
31
Walleye Trading
New York
| $6K | -$14.4K | -1,800 | -67% |
|
|
TRCT
32
Tower Research Capital (TRC)
New York
| $4K | +$4.17K | +521 | New |
|
33
Bank of America
Charlotte,
North Carolina
| $3K | – | – | – |
|
34
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | -$1.2K | -150 | -38% |
|
|
CAM
35
ClariVest Asset Management
San Diego,
California
| – | -$90K | -10,735 | Closed |
|
|
AIM
36
Acrospire Investment Management
Chicago,
Illinois
| – | -$80K | -9,511 | Closed |
|
ENZY Hedge Fund Activity: Q3 2016 in Review
34 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Enzymotec Ltd (ENZY) for Q3 2016, worth a combined $57.2M — down 15% from $67.3M a quarter earlier.
Fund positioning in ENZY was balanced in Q3 2016: 2 funds opened new positions, 2 closed out, 13 added to existing stakes and 13 trimmed.
The largest buyer was Tiger Management, adding an estimated $803K. The largest seller was Goldman Sachs, cutting an estimated $1.74M.
- 34 institutional investors held Enzymotec Ltd (ENZY) as of Q3 2016, unchanged from Q2 2016.
- Funds reported $57.2M of Enzymotec Ltd stock for Q3 2016, down 15% quarter-over-quarter.
- 2 funds opened new Enzymotec Ltd positions in Q3 2016 and 2 closed out, a net change of 0 holders.
- The largest Enzymotec Ltd buyer in Q3 2016 was Tiger Management, an estimated $803K added.
- The largest Enzymotec Ltd seller in Q3 2016 was Goldman Sachs, an estimated $1.74M sold.
Based on aggregated 13F filings for Q3 2016.